A Phase 4 interventional study of Dupilumab SAR231893 in Dermatitis Atopic, sponsored by Sanofi. Completed at 3 sites in 2 countries. Open to participants aged 6 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 35th largest by enrollment, is one of 5 that started in 2021, is one of 24 in phase 4, and was the 31st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
43 studies in Dermatitis, Atopic by Sanofi: 5 open now, 16 under way, 4 of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is one of 8 in phase 4, and was the 11th registered.
Sanofi’s Dermatitis, Atopic studies by the year they started, since 2006.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Sanofi’s 43 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic dermatitis (AD) treated with dupilumab.
Secondary Objectives:
Total study duration including screening and follow-up was 32 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Atopic dermatitis participants:
Healthy volunteers:
- Age and gender matched (match on age ±2 years) to a selected AD participant by study site.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants with moderate-to-severe atopic dermatitis (AD) and with baseline body weight more than or equal to (\>=) 15 kilograms (kg) and less than (\<) 30 kg received a subcutaneous (SC) loading dose of dupilumab 600 milligrams (mg) (2 injections of dupilumab 300 mg) on Day 1 (Week 0) followed by dupilumab 300 mg SC injection every 4 weeks (Q4W), from Week 4 to Week 12. Pediatric participants with body weight \>=30 kg and \<60 kg received SC loading dose of dupilumab 400 mg (2 injections of dupilumab 200 mg) on Day 1 (Week 0), followed by dupilumab 200 mg SC injection every 2 weeks (Q2W), from Week 2 to Week 14.
Drug: Dupilumab SAR231893
Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to selected AD participants, received no treatment, but were monitored in a similar way as AD participants.
Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Also known as: REGN668
Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM).
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that was used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Week 16
Percent Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline ('predefined skin area'). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Absolute Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Percent Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Absolute Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Percent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Absolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Percent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Absolute Change From Baseline in AUC of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS (nsts) used to reflect the overall integrity of stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Percent Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS reflect the overall integrity of the stratum corneum. Non-LS areas for TEWL assessment \& STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10, 15 \& 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before \& after 5, 10, 15 \&20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Absolute Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Non-LS areas for TEWL assessment and STS were identified at baseline(predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10,15 and 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline(Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Percent Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over a defined number of STS used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment \& STS were identified at baseline(predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10,15 \& 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC: composite measure before \& after 5, 10, 15\& 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 conducted on first spot. Percent Change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Absolute Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Normal skin areas for TEWL assessment and STS identified at baseline(predefined skin area). Within predefined Normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS and after 5, 10,15 and 20 STS on pre-defined Normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10,15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participant were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Secondary: Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on the first spot. Absolute change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.
Time frame: Baseline, Days 57, 113 and 197
Study was conducted at 3 active sites in the United States and United Kingdom. A total of 43 participants were screened between 19 Feb 2021 and 12 May 2022, out of which 41 were enrolled and 2 were screen failures due to not meeting inclusion criteria.
| Milestone | Healthy Volunteers | Atopic Dermatitis Participants |
|---|---|---|
| Started | 18 | 23 |
| Completed | 18 | 23 |
| Not completed | 0 | 0 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM).
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16 | -38.5633 ± 27.1211 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16 | -33.1336 ± 28.1613 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that was used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16 | -35.6671 ± 31.2267 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16 | -6.1452 ± 67.9496 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16 | -13.6682 ± 33.3065 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16 | 13.2578 ± 64.3880 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16 | 5.9327 ± 32.0123 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16 | -33.3119 ± 32.7125 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16 | -33.4028 ± 31.1957 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16 | -7.6067 ± 54.7945 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16 | -12.6576 ± 30.0412 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16 | 4.5364 ± 42.7525 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16 | 0.1082 ± 17.5865 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16 | -34.7741 ± 31.0541 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16 | -33.1024 ± 36.2286 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16 | -3.8193 ± 74.6263 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16 | -10.9488 ± 31.1300 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16 | 0.7091 ± 25.0615 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16 | -1.3482 ± 6.6778 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16 | -4.8842 ± 70.5670 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16 | -9.0771 ± 21.3022 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16 | 1.4464 ± 26.7257 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16 | -1.0255 ± 4.3657 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline ('predefined skin area'). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Day 8 - Spot 1 | -7.1596 ± 36.6637 |
| Day 8 - Spot 2 | -6.3439 ± 33.8145 |
| Day 8 - Spot 3 | -7.0747 ± 28.3554 |
| Day 15 - Spot 1 | -15.3096 ± 45.6163 |
| Day 15 - Spot 2 | -11.0740 ± 35.5483 |
| Day 15 - Spot 3 | -8.1780 ± 44.9382 |
| Day 22 - Spot 1 | -30.3070 ± 33.6643 |
| Day 22 - Spot 2 | -29.1730 ± 31.7167 |
| Day 22 - Spot 3 | -27.0015 ± 25.8528 |
| Day 29 - Spot 1 | -37.8349 ± 24.7709 |
| Day 29 - Spot 2 | -33.0139 ± 27.8560 |
| Day 29 - Spot 3 | -32.7080 ± 28.8445 |
| Day 43 - Spot 1 | -37.8675 ± 29.0275 |
| Day 43 - Spot 2 | -36.1625 ± 28.9829 |
| Day 43 - Spot 3 | -32.9996 ± 33.2028 |
| Day 57 - Spot 1 | -38.2449 ± 40.0558 |
| Day 57 - Spot 2 | -39.3104 ± 27.6888 |
| Day 57 - Spot 3 | -35.8992 ± 27.9526 |
| Day 85 - Spot 1 | -45.6060 ± 23.2839 |
| Day 85 - Spot 2 | -40.8609 ± 30.8002 |
| Day 85 - Spot 3 | -41.1371 ± 24.5842 |
| Day 113 - Spot 1 | -36.0863 ± 33.7259 |
| Day 113 - Spot 2 | -37.4815 ± 30.8507 |
| Day 113 - Spot 3 | -32.3491 ± 29.2966 |
| Day 155 - Spot 1 | -40.9536 ± 30.9966 |
| Day 155 - Spot 2 | -20.8463 ± 50.6518 |
| Day 155 - Spot 3 | -31.3185 ± 42.0614 |
| Day 197 - Spot 1 | -35.2305 ± 45.8818 |
| Day 197 - Spot 2 | -30.3358 ± 48.3028 |
| Day 197 - Spot 3 | -36.5267 ± 37.7230 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Day 8 - Spot 1 | -9.3486 ± 21.2256 |
| Day 8 - Spot 2 | -6.0491 ± 17.5810 |
| Day 8 - Spot 3 | -3.1965 ± 14.4640 |
| Day 15 - Spot 1 | -15.4336 ± 25.0975 |
| Day 15 - Spot 2 | -9.8073 ± 19.7385 |
| Day 15 - Spot 3 | -7.6682 ± 21.9239 |
| Day 22 - Spot 1 | -23.0157 ± 26.8847 |
| Day 22 - Spot 2 | -20.7186 ± 23.4149 |
| Day 22 - Spot 3 | -15.6557 ± 20.1212 |
| Day 29 - Spot 1 | -23.9585 ± 21.7106 |
| Day 29 - Spot 2 | -21.2010 ± 21.2593 |
| Day 29 - Spot 3 | -17.9170 ± 19.7310 |
| Day 43 - Spot 1 | -27.0535 ± 28.0249 |
| Day 43 - Spot 2 | -24.5188 ± 25.6684 |
| Day 43 - Spot 3 | -20.7018 ± 22.5936 |
| Day 57 - Spot 1 | -25.1221 ± 27.0210 |
| Day 57 - Spot 2 | -24.2358 ± 24.6028 |
| Day 57 - Spot 3 | -20.3379 ± 20.3751 |
| Day 85 - Spot 1 | -29.1917 ± 24.3114 |
| Day 85 - Spot 2 | -24.4494 ± 24.2054 |
| Day 85 - Spot 3 | -23.1056 ± 20.4692 |
| Day 113 - Spot 1 | -24.6678 ± 27.8013 |
| Day 113 - Spot 2 | -23.2878 ± 26.5670 |
| Day 113 - Spot 3 | -17.9028 ± 22.2483 |
| Day 155 - Spot 1 | -28.2564 ± 29.2212 |
| Day 155 - Spot 2 | -18.7786 ± 31.4917 |
| Day 155 - Spot 3 | -19.8921 ± 27.8520 |
| Day 197 - Spot 1 | -27.4493 ± 33.7080 |
| Day 197 - Spot 2 | -22.5607 ± 31.7696 |
| Day 197 - Spot 3 | -22.0860 ± 27.1286 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Day 8 - Spot 1 | 41.0825 ± 91.3744 |
| Day 8 - Spot 2 | 13.5236 ± 49.3733 |
| Day 8 - Spot 3 | 9.7943 ± 43.9272 |
| Day 15 - Spot 1 | 19.0612 ± 58.1703 |
| Day 15 - Spot 2 | 9.6866 ± 52.6831 |
| Day 15 - Spot 3 | 13.2574 ± 55.8095 |
| Day 22 - Spot 1 | -3.9277 ± 35.9880 |
| Day 22 - Spot 2 | 8.9306 ± 70.2617 |
| Day 22 - Spot 3 | 0.4973 ± 49.5636 |
| Day 29 - Spot 1 | -8.9585 ± 39.0443 |
| Day 29 - Spot 2 | -10.5728 ± 35.2672 |
| Day 29 - Spot 3 | -13.0407 ± 44.5264 |
| Day 43 - Spot 1 | -15.6919 ± 29.7995 |
| Day 43 - Spot 2 | -21.6885 ± 30.1255 |
| Day 43 - Spot 3 | -16.2025 ± 42.7984 |
| Day 57 - Spot 1 | -24.5008 ± 26.9801 |
| Day 57 - Spot 2 | -27.6040 ± 23.0969 |
| Day 57 - Spot 3 | -25.7321 ± 33.1310 |
| Day 85 - Spot 1 | -21.9316 ± 34.3620 |
| Day 85 - Spot 2 | -16.7008 ± 62.4384 |
| Day 85 - Spot 3 | -29.2721 ± 40.0673 |
| Day 113 - Spot 1 | -20.4359 ± 42.6948 |
| Day 113 - Spot 2 | -23.1303 ± 41.2717 |
| Day 113 - Spot 3 | -27.4981 ± 33.5326 |
| Day 155 - Spot 1 | -6.7535 ± 73.4261 |
| Day 155 - Spot 2 | -16.3903 ± 41.9864 |
| Day 155 - Spot 3 | -19.3970 ± 46.5302 |
| Day 197 - Spot 1 | -23.3812 ± 39.5978 |
| Day 197 - Spot 2 | -27.3104 ± 32.8267 |
| Day 197 - Spot 3 | -22.1813 ± 40.5124 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Day 8 - Spot 1 | 4.1752 ± 14.1047 |
| Day 8 - Spot 2 | -0.0248 ± 11.8585 |
| Day 8 - Spot 3 | -0.3413 ± 9.8571 |
| Day 15 - Spot 1 | 0.4723 ± 9.7975 |
| Day 15 - Spot 2 | -2.6176 ± 13.1001 |
| Day 15 - Spot 3 | -1.0171 ± 11.3877 |
| Day 22 - Spot 1 | -3.8162 ± 10.3046 |
| Day 22 - Spot 2 | -3.5735 ± 16.4593 |
| Day 22 - Spot 3 | -5.3314 ± 12.8392 |
| Day 29 - Spot 1 | -5.3400 ± 10.8674 |
| Day 29 - Spot 2 | -6.7411 ± 13.5999 |
| Day 29 - Spot 3 | -9.5905 ± 14.0754 |
| Day 43 - Spot 1 | -6.7424 ± 9.7834 |
| Day 43 - Spot 2 | -8.8444 ± 12.4876 |
| Day 43 - Spot 3 | -10.5600 ± 14.1984 |
| Day 57 - Spot 1 | -8.2874 ± 8.5546 |
| Day 57 - Spot 2 | -9.7772 ± 11.7879 |
| Day 57 - Spot 3 | -11.9179 ± 13.1662 |
| Day 85 - Spot 1 | -8.2272 ± 11.6158 |
| Day 85 - Spot 2 | -7.6171 ± 16.1511 |
| Day 85 - Spot 3 | -13.1811 ± 14.4647 |
| Day 113 - Spot 1 | -8.0665 ± 11.9970 |
| Day 113 - Spot 2 | -9.2906 ± 13.7202 |
| Day 113 - Spot 3 | -11.2776 ± 12.9322 |
| Day 155 - Spot 1 | -7.0229 ± 15.4066 |
| Day 155 - Spot 2 | -7.0408 ± 12.8562 |
| Day 155 - Spot 3 | -10.4414 ± 14.5146 |
| Day 197 - Spot 1 | -8.9200 ± 11.3266 |
| Day 197 - Spot 2 | -11.2953 ± 15.3452 |
| Day 197 - Spot 3 | -11.1625 ± 16.2087 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Day 8 - Spot 1 | 5.0103 ± 39.4170 |
| Day 8 - Spot 2 | -8.7688 ± 20.5764 |
| Day 8 - Spot 3 | -3.8203 ± 19.5160 |
| Day 15 - Spot 1 | 1.9837 ± 27.7012 |
| Day 15 - Spot 2 | -4.0758 ± 22.1886 |
| Day 15 - Spot 3 | -1.7489 ± 21.1652 |
| Day 22 - Spot 1 | -2.6655 ± 19.8558 |
| Day 22 - Spot 2 | 7.5939 ± 22.7859 |
| Day 22 - Spot 3 | 3.8603 ± 12.1068 |
| Day 29 - Spot 1 | -1.7648 ± 21.4820 |
| Day 29 - Spot 2 | 9.9969 ± 14.4219 |
| Day 29 - Spot 3 | 8.4098 ± 15.2499 |
| Day 43 - Spot 1 | 1.4115 ± 27.8012 |
| Day 43 - Spot 2 | 2.9668 ± 30.1272 |
| Day 43 - Spot 3 | 13.4093 ± 35.9985 |
| Day 57 - Spot 1 | 7.6533 ± 24.0747 |
| Day 57 - Spot 2 | 5.3384 ± 17.9065 |
| Day 57 - Spot 3 | 12.6926 ± 24.7125 |
| Day 85 - Spot 1 | 5.2021 ± 23.1397 |
| Day 85 - Spot 2 | 0.7096 ± 19.5448 |
| Day 85 - Spot 3 | 5.1021 ± 20.0690 |
| Day 113 - Spot 1 | 2.6054 ± 26.2241 |
| Day 113 - Spot 2 | 9.4234 ± 24.1533 |
| Day 113 - Spot 3 | 17.0905 ± 16.4596 |
| Day 155 - Spot 1 | 10.3105 ± 52.8138 |
| Day 155 - Spot 2 | 11.2398 ± 22.7028 |
| Day 155 - Spot 3 | 11.5842 ± 27.2298 |
| Day 197 - Spot 1 | 3.3636 ± 26.9400 |
| Day 197 - Spot 2 | 5.3772 ± 19.9583 |
| Day 197 - Spot 3 | 12.0900 ± 24.8690 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| Day 8 - Spot 1 | -0.2508 ± 4.8798 |
| Day 8 - Spot 2 | -1.8215 ± 3.3907 |
| Day 8 - Spot 3 | -0.7869 ± 2.9791 |
| Day 15 - Spot 1 | -0.5786 ± 3.3947 |
| Day 15 - Spot 2 | -1.0029 ± 3.4320 |
| Day 15 - Spot 3 | -0.3829 ± 3.3925 |
| Day 22 - Spot 1 | -0.7575 ± 3.2991 |
| Day 22 - Spot 2 | 1.0233 ± 3.7207 |
| Day 22 - Spot 3 | 0.6433 ± 2.0759 |
| Day 29 - Spot 1 | -1.1631 ± 3.1429 |
| Day 29 - Spot 2 | 0.8585 ± 1.8609 |
| Day 29 - Spot 3 | 0.7938 ± 1.7624 |
| Day 43 - Spot 1 | -1.0129 ± 4.0940 |
| Day 43 - Spot 2 | -0.8357 ± 4.7103 |
| Day 43 - Spot 3 | 0.7057 ± 5.1247 |
| Day 57 - Spot 1 | 0.6308 ± 4.1304 |
| Day 57 - Spot 2 | 0.2283 ± 2.6839 |
| Day 57 - Spot 3 | 1.5142 ± 4.1943 |
| Day 85 - Spot 1 | 0.0164 ± 3.2348 |
| Day 85 - Spot 2 | -0.3221 ± 3.5460 |
| Day 85 - Spot 3 | 0.2779 ± 3.8491 |
| Day 113 - Spot 1 | -0.3791 ± 3.4231 |
| Day 113 - Spot 2 | 0.4882 ± 2.5528 |
| Day 113 - Spot 3 | 2.0527 ± 2.1762 |
| Day 155 - Spot 1 | -0.9293 ± 6.5972 |
| Day 155 - Spot 2 | 0.6880 ± 3.7653 |
| Day 155 - Spot 3 | 0.4793 ± 4.5057 |
| Day 197 - Spot 1 | -0.6153 ± 4.8187 |
| Day 197 - Spot 2 | -0.0427 ± 3.6560 |
| Day 197 - Spot 3 | 0.6747 ± 4.8536 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Day 57 | -38.2091 ± 25.6654 |
| Day 113 | -34.0025 ± 29.1866 |
| Day 197 | -40.0143 ± 26.9737 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS (nsts) used to reflect the overall integrity of stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.
| nsts*grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Day 57 | -632.0224 ± 494.4981 |
| Day 113 | -608.1875 ± 601.7999 |
| Day 197 | -659.4033 ± 570.2425 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS reflect the overall integrity of the stratum corneum. Non-LS areas for TEWL assessment \& STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10, 15 \& 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before \& after 5, 10, 15 \&20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| Day 57 | -21.7570 ± 29.1137 |
| Day 113 | -10.8940 ± 50.7679 |
| Day 197 | -28.6897 ± 26.0253 |
TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Non-LS areas for TEWL assessment and STS were identified at baseline(predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10,15 and 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline(Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.
| nsts*grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| Day 57 | -281.9579 ± 342.1271 |
| Day 113 | -217.7544 ± 462.0173 |
| Day 197 | -367.5469 ± 340.1948 |
TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over a defined number of STS used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment \& STS were identified at baseline(predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10,15 \& 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC: composite measure before \& after 5, 10, 15\& 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 conducted on first spot. Percent Change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| Day 57 | 3.2794 ± 15.6493 |
| Day 113 | 3.4753 ± 30.2504 |
| Day 197 | -10.1582 ± 18.4753 |
TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Normal skin areas for TEWL assessment and STS identified at baseline(predefined skin area). Within predefined Normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS and after 5, 10,15 and 20 STS on pre-defined Normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10,15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.
| nsts*grams per square meter per hour | Healthy Volunteers |
|---|---|
| Day 57 | 16.8563 ± 70.4582 |
| Day 113 | 2.5568 ± 197.8379 |
| Day 197 | -72.9050 ± 108.8230 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participant were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| After 5 STS: Day 57 | -42.2019 ± 22.5314 |
| After 5 STS: Day 113 | -38.5633 ± 27.1211 |
| After 5 STS: Day 197 | -36.4601 ± 47.5902 |
| After 10 STS: Day 57 | -40.4595 ± 27.4572 |
| After 10 STS: Day 113 | -34.7741 ± 31.0541 |
| After 10 STS: Day 197 | -39.9440 ± 29.2084 |
| After 15 STS: Day 57 | -41.6561 ± 24.0960 |
| After 15 STS: Day 113 | -33.3119 ± 32.7125 |
| After 15 STS: Day 197 | -38.4286 ± 27.0978 |
| After 20 STS: Day 57 | -34.8297 ± 23.0520 |
| After 20 STS: Day 113 | -33.1336 ± 28.1613 |
| After 20 STS: Day 197 | -35.6561 ± 23.0987 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| After 5 STS: Day 57 | -31.3795 ± 25.4943 |
| After 5 STS: Day 113 | -31.1761 ± 31.3420 |
| After 5 STS: Day 197 | -33.5753 ± 40.1857 |
| After 10 STS: Day 57 | -36.4267 ± 31.1758 |
| After 10 STS: Day 113 | -33.1024 ± 36.2286 |
| After 10 STS: Day 197 | -35.8254 ± 33.3362 |
| After 15 STS: Day 57 | -37.9779 ± 23.3049 |
| After 15 STS: Day 113 | -33.4028 ± 31.1957 |
| After 15 STS: Day 197 | -36.0843 ± 27.5612 |
| After 20 STS: Day 57 | -35.0726 ± 23.5765 |
| After 20 STS: Day 113 | -35.6671 ± 31.2267 |
| After 20 STS: Day 197 | -34.5257 ± 23.9001 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.
| percent change | Atopic Dermatitis Participants |
|---|---|
| After 5 STS: Day 57 | -24.8218 ± 31.4633 |
| After 5 STS: Day 113 | -4.8842 ± 70.5670 |
| After 5 STS: Day 197 | -29.7635 ± 44.0691 |
| After 10 STS: Day 57 | -20.3640 ± 43.5318 |
| After 10 STS: Day 113 | -3.8193 ± 74.6263 |
| After 10 STS: Day 197 | -29.6888 ± 38.9536 |
| After 15 STS: Day 57 | -18.4348 ± 33.3647 |
| After 15 STS: Day 113 | -7.6067 ± 54.7945 |
| After 15 STS: Day 197 | -27.2268 ± 25.1580 |
| After 20 STS: Day 57 | -19.2584 ± 30.1343 |
| After 20 STS: Day 113 | -6.1452 ± 67.9496 |
| After 20 STS: Day 197 | -22.3311 ± 23.0908 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on the first spot. Absolute change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.
| grams per square meter per hour | Atopic Dermatitis Participants |
|---|---|
| After 5 STS: Day 57 | -11.8526 ± 12.6180 |
| After 5 STS: Day 113 | -9.0771 ± 21.3022 |
| After 5 STS: Day 197 | -15.8375 ± 18.0369 |
| After 10 STS: Day 57 | -15.0005 ± 20.1721 |
| After 10 STS: Day 113 | -10.9488 ± 31.1300 |
| After 10 STS: Day 197 | -21.2825 ± 23.2998 |
| After 15 STS: Day 57 | -16.1047 ± 26.4807 |
| After 15 STS: Day 113 | -12.6576 ± 30.0412 |
| After 15 STS: Day 197 | -21.9006 ± 19.2885 |
| After 20 STS: Day 57 | -18.5800 ± 30.3574 |
| After 20 STS: Day 113 | -13.6682 ± 33.3065 |
| After 20 STS: Day 197 | -20.0575 ± 16.1537 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| percent change | Healthy Volunteers |
|---|---|
| After 5 STS: Day 57 | 4.9595 ± 16.0950 |
| After 5 STS: Day 113 | 1.4464 ± 26.7257 |
| After 5 STS: Day 197 | -1.6729 ± 25.2293 |
| After 10 STS: Day 57 | 4.0996 ± 20.4647 |
| After 10 STS: Day 113 | 0.7091 ± 25.0615 |
| After 10 STS: Day 197 | -7.4475 ± 19.7215 |
| After 15 STS: Day 57 | 3.2339 ± 20.9086 |
| After 15 STS: Day 113 | 4.5364 ± 42.7525 |
| After 15 STS: Day 197 | -14.0103 ± 18.5552 |
| After 20 STS: Day 57 | 4.3494 ± 27.5527 |
| After 20 STS: Day 113 | 13.2578 ± 64.3880 |
| After 20 STS: Day 197 | -18.0480 ± 22.6193 |
TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.
| grams per square meter per hour | Healthy Volunteers |
|---|---|
| After 5 STS: Day 57 | 0.5642 ± 3.3355 |
| After 5 STS: Day 113 | -1.0255 ± 4.3657 |
| After 5 STS: Day 197 | -1.5627 ± 5.2934 |
| After 10 STS: Day 57 | 0.2825 ± 4.5142 |
| After 10 STS: Day 113 | -1.3482 ± 6.6778 |
| After 10 STS: Day 197 | -3.0880 ± 5.2754 |
| After 15 STS: Day 57 | 0.4750 ± 6.4442 |
| After 15 STS: Day 113 | 0.1082 ± 17.5865 |
| After 15 STS: Day 197 | -5.8847 ± 8.1968 |
| After 20 STS: Day 57 | 3.4683 ± 9.8235 |
| After 20 STS: Day 113 | 5.9327 ± 32.0123 |
| After 20 STS: Day 197 | -7.4760 ± 9.3514 |
Collected over For AD participants: from first dose (i.e., Day 1) of IMP administration up to end of treatment visit (i.e., Day 113). For healthy volunteers: from signature of consent form to end of study (i.e., up to Day 197). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Volunteers | 0/18 (0%) | 0/18 (0%) | 6/18 (33.3%) |
| Atopic Dermatitis Participant | 0/23 (0%) | 0/23 (0%) | 21/23 (91.3%) |
| Event | Healthy Volunteers | Atopic Dermatitis Participant |
|---|---|---|
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 0/18 | 9/23 |
| Medical Device Site HaemorrhageGeneral disorders | 0/18 | 6/23 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/18 | 4/23 |
| HeadacheNervous system disorders | 1/18 | 3/23 |
| UrticariaSkin and subcutaneous tissue disorders | 0/18 | 3/23 |
| PyrexiaGeneral disorders | 2/18 | 0/23 |
| Eye PruritusEye disorders | 0/18 | 2/23 |
| Covid-19Infections and infestations | 1/18 | 1/23 |
| Skin Bacterial InfectionInfections and infestations | 1/18 | 0/23 |
| LymphadenopathyBlood and lymphatic system disorders | 1/18 | 0/23 |
Analysis was performed on modified intent-to-treat (mITT) population which included all enrolled AD participants who received at least 1 dose of investigational medicinal product (IMP) and all enrolled healthy volunteers who had at least 1 TEWL/STS assessment performed, irrespective of compliance with protocol and procedures. If prohibited therapies used for AD, only visits prior to rescue treatment were considered.
| Age, Continuous(years) | Healthy Volunteers | Atopic Dermatitis Participants | Total |
|---|---|---|---|
| Mean | 8.2 ± 1.8 | 7.8 ± 1.6 | 8.0 ± 1.7 |
| Sex: Female, Male(Participants) | Healthy Volunteers | Atopic Dermatitis Participants | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 10 | 15 | 25 |
| Race (NIH/OMB)(Participants) | Healthy Volunteers | Atopic Dermatitis Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 9 | 16 | 25 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2021 to primary completion in Sep 2022, 18 months.
Results were first posted in Oct 2023, 1 year 1 month after primary completion.
Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab